Aurobindo Pharma (AUROPHARMA) — Announcement

📢 Key Event
US FDA inspection completed at Apitoria Pharma's Unit-VI facility with three procedural observations.

💡 Investor Takeaway
The FDA inspection outcome poses no immediate financial or operational risk but requires procedural follow-up, maintaining investor confidence in quality compliance.

Aurobindo Pharma announced the completion of a US FDA inspection at its Apitoria Pharma subsidiary's Unit-VI facility in Andhra Pradesh, which concluded with three procedural observations requiring a response within a stipulated timeline, reaffirming its commitment to quality standards and pledging to update exchanges on future developments.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AUROPHARMA ✨ Ask AI About This

About Aurobindo Pharma Ltd (AUROPHARMA)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹96,836.1 Cr P/E: 26.3 ROE: 9.8% ROCE: 12.8% Div Yield: 0.24%

View full AUROPHARMA stock details →

📡 Get AI alerts when AUROPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AUROPHARMA — Free

💡 Ask AI about this filing

"How will Apitoria Pharma address the three FDA observations?" "What is the expected timeline for FDA response resolution?" "How does this inspection impact Aurobindo's US market approval timeline?"

Ask AI Free →

📊 More AUROPHARMA filings

See all AUROPHARMA filings →

🔥 Also filed on 28 August 2026

BLIL Balmer Lawrie Investment Ltd Annual Report 520075 Samkrg Pistons & Rings Ltd Annual Report 507998 Simmonds Marshall Ltd Annual Report BLUEDART Blue Dart Express Ltd Annual Report TTL T T Ltd Insider Trading LTF L&T Finance Ltd Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AUROPHARMA files new disclosures

Track AUROPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AUROPHARMA — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd